Brian C. Stephenson Sells 4,155 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) CFO Brian C. Stephenson sold 4,155 shares of BridgeBio Pharma stock in a transaction on Monday, August 19th. The shares were sold at an average price of $24.69, for a total value of $102,586.95. Following the completion of the transaction, the chief financial officer now owns 85,192 shares in the company, valued at $2,103,390.48. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

BridgeBio Pharma Price Performance

BridgeBio Pharma stock traded up $0.49 during mid-day trading on Tuesday, reaching $25.66. 999,601 shares of the company traded hands, compared to its average volume of 1,769,916. BridgeBio Pharma, Inc. has a fifty-two week low of $21.62 and a fifty-two week high of $44.32. The firm’s fifty day moving average is $26.01 and its two-hundred day moving average is $28.37. The company has a market capitalization of $4.80 billion, a price-to-earnings ratio of -7.82 and a beta of 1.06.

BridgeBio Pharma (NASDAQ:BBIO) last released its earnings results on Thursday, August 1st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.00) by $0.61. The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $3.96 million. During the same period in the previous year, the company earned ($0.98) earnings per share. BridgeBio Pharma’s revenue was up 32.1% on a year-over-year basis. As a group, equities research analysts predict that BridgeBio Pharma, Inc. will post -3.2 earnings per share for the current year.

Analyst Upgrades and Downgrades

BBIO has been the topic of several analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 target price on shares of BridgeBio Pharma in a research note on Monday, July 1st. JPMorgan Chase & Co. lowered their price target on shares of BridgeBio Pharma from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 7th. Evercore ISI reduced their price objective on shares of BridgeBio Pharma from $50.00 to $45.00 and set an “outperform” rating for the company in a research note on Wednesday, August 7th. UBS Group lowered their target price on shares of BridgeBio Pharma from $51.00 to $47.00 and set a “buy” rating for the company in a research note on Tuesday, May 28th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $43.00 price target on shares of BridgeBio Pharma in a report on Monday, August 5th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $48.09.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the company. Wellington Management Group LLP boosted its position in BridgeBio Pharma by 5.3% in the fourth quarter. Wellington Management Group LLP now owns 1,495,114 shares of the company’s stock valued at $60,358,000 after buying an additional 75,564 shares during the last quarter. UBS Group AG boosted its holdings in shares of BridgeBio Pharma by 545.9% in the 4th quarter. UBS Group AG now owns 985,510 shares of the company’s stock valued at $39,785,000 after acquiring an additional 832,940 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of BridgeBio Pharma by 22.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 803,956 shares of the company’s stock worth $24,859,000 after acquiring an additional 145,594 shares during the period. Vanguard Group Inc. raised its holdings in shares of BridgeBio Pharma by 3.3% during the first quarter. Vanguard Group Inc. now owns 13,222,126 shares of the company’s stock worth $408,828,000 after purchasing an additional 421,832 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new position in BridgeBio Pharma during the fourth quarter valued at $7,474,000. 99.85% of the stock is owned by institutional investors and hedge funds.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.